<DOC>
	<DOCNO>NCT01420432</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy mesenchymal stem cell ( MSCs ) derive human umbilical cord/placenta dose 1.0E+6 MSC/kg subject therapy Ankylosing spondylitis ( AS )</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells Treat Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description>Ankylosing spondylitis ( AS ) chronic , progressive inflammatory rheumatic disease involve primarily sacroiliac joint axial skeleton . The main clinical feature back pain progressive stiffness spine . Oligoarthritis hips shoulder , enthesopathy , anterior uveitis common , involvement heart lung rare . The current understanding pathogenesis disorder limited.It mainly hereditary susceptibility ( eg hla-b27 ) , infection autoimmunity . Although traditional drug , Nonsteroidal antiinflammatory drug ( NSAIDs ) disease-modifying antirheumatic drug ( DMARDs MTX , SASP OR thalidomide ) steroid use treatment AS , however , many study indicate overall response drug satisfy . Addition , severe side effect drug also observe . The management AS patient therefore remains unsatisfactory targeted therapy need . Human MSCs isolate human umbilical cord/placenta show immunoregulatory , immunosuppressive , stimulating hematopoiesis tissue repair property . This study evaluate safety effectiveness MSC transplantation AS patient . This study last 2 3 year . Participants randomly assign receive either MSC transplant +DMARDs therapy ( experimental group ) DMARDs therapy ( control group ) . Patients undergo MSC transplant start study Day 0 . After 3 month , patient receive second MSC transplantation . After six twelve month first transplantation , patient evaluate .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>1 . Patient age 18~60 year old plan infuse MSCs . 2 . Diagnosis `` Definite AS '' ( arthritis spine ) define modified New York criteria 3 . Stable dos sulfasalazine , methotrexate , thalidomide , hydroxychloroquine , lowdose corticosteroid , NSAIDs permit 4 . Patients must ECOG 0~2 . 5 . No moderate sever organ dysfunction : Ejection fraction &gt; 45 % ; Creatinine &lt; 176 umol/L . 6 . No severe infection . 7 . Each patient must sign write informed consent . 1 . Other serious concomitant disease ( uncontrolled/severe kidney , liver , haematological , gastrointestinal , endocrine , cardiovascular , pulmonary , neurological cerebral disease ) 2 . Psychiatric condition would limit informed consent . 3 . HIV , hepatitis B C , tuberculosis , infection 4 . Positive Pregnancy Test lactation 5 . Patient enrol another clinical trial study within last 4 week . 6 . Contraindications MSC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Umbilical Cord/placenta-Derived MSC</keyword>
	<keyword>Transplantation</keyword>
</DOC>